The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to US$1.3 billion to boost its pipeline beyond its blockbuster weight-loss and diabetes drugs.